Integrating Immunotherapy with Locoregional Treatment in Hepatocellular Carcinoma: Mechanistic Insights and Emerging Clinical Strategies
Year: 2026
Type: article
Abstract: Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer worldwide and the third leading cause of cancer-related mortality. Chronic viral hepatitis and metabolic liver disease are major contributors to its development. Many patients present with intermediate or advanced disease, for which treatment selection depends on tumor burden, vascular involvement, liver function, performance status, and multidisciplinary assessment. This review evaluates clinical evidence for combining locoregional therapies, including transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), thermal ablation, and transarterial radioembolization (TARE), with immune checkpoint inhibitors and antiangiogenic agents. In the phase III LEAP-012 trial, lenvatinib plus pembrolizumab with TACE improved median progression-free survival (PFS) compared with TACE alone (14.6 versus 10.0 months; hazard ratio 0.66), while the interim overall-survival (OS) difference was not statistically significant. Grade 3 or higher treatment-related adverse events were more frequent with the triplet regimen (71% versus 32%). EMERALD-1 also reported a PFS benefit for durvalumab plus bevacizumab with TACE, whereas mature OS benefit has not been established. Evidence for TACE-based combinations is more developed than evidence for HAIC-, ablation-, or TARE-based combinations, many of which remain investigational or are supported mainly by nonrandomized studies. Proposed mechanisms include immunogenic cell death, tumor-antigen release, changes in immune-checkpoint signaling, and vascular remodeling. Clinical implementation requires careful patient selection, preservation of hepatic reserve, monitoring for cumulative toxicity, and consideration of quality of life. Ongoing randomized trials, biomarker research, and precision-treatment approaches are expected to clarify which patients benefit from these combinations and how treatment should be sequenced.
Source: ACS Omega
Institution: Dr. D.Y. Patil Vidyapeeth, Pune
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: hepatocellular carcinoma, immunotherapy, locoregional therapy, transarterial chemoembolization, hepatic arterial infusion chemotherapy, thermal ablation, radioembolization, immune checkpoint inhibitors, lenvatinib, pembrolizumab, durvalumab, bevacizumab, angiogenesis inhibitors, immunogenic cell death, tumor antigen release, immune checkpoint signaling, vascular remodeling, treatment sequencing, patient selection, treatment toxicity, biomarkers
Open Access status: gold
Estimated APC paid: $1,935
OpenAlex ID: W7236498010
